Amgen: Biotech Giant's Stock Struggles, Long-Term Hope?

Amgen: Biotech giant or busted stock? Despite strong earnings and raised guidance, Amgen's stock is down, puzzling investors. Is their experimental weight-loss drug MariTide the key to recovery, or will regulatory headwinds and market skepticism keep this heavyweight grounded? Find out what Wall Street analysts predict for Amgen's future. Hosted on Acast. See acast.com/privacy for more information.